Hepalink proposes governance overhaul, new independent director

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKEX:9989) is set to hold an Extraordinary General Meeting (EGM) on December 16, 2025, to vote on major corporate governance changes. The proposals include abolishing the supervisory committee, amending the articles of association, and revising internal corporate governance measures. The supervisory committee’s powers and duties will be transferred to the board's audit committee.

Concurrently, Dr. Lu Chuan's six-year term as an independent non-executive director will expire on December 16, 2025. The board proposes electing Mr. Pu Hong as a new independent non-executive director for a three-year term. Mr. Pu, aged 61, holds master's degrees in accounting and finance and an On-The-Job Doctorate, and has extensive experience in corporate advisory. If elected, he will receive an annual director's fee of RMB100,000.

These changes are designed to align with the PRC Company Law and Guidelines for Articles of Association of Listed Companies revised in March 2025. The board believes these amendments will not compromise shareholder protection and will ensure ongoing compliance with regulatory standards.